Pharmacodynamic Interactions — MCQs
Pharmacodynamics deals with:-
Which of the following statements is true regarding competitive reversible antagonism?
Which of the following is the most effective antagonist for morphine overdose?
Which of the following combinations does not show synergistic action?
A patient on digoxin therapy presents with atrial fibrillation and controlled ventricular rate. Upon evaluation, the patient's serum digoxin levels are elevated compared to previous values. Which of the following concomitant medications is most likely to have contributed to the enhanced digoxin toxicity?
Identify the correct match, regarding the drug and its adverse effect.
A 78-year-old woman is brought to the clinic by her daughter due to concerns about her mother's mood. The patient's husband of 48 years passed away six months ago after a lengthy illness due to metastatic colon cancer. Since then, she reports having a poor appetite, decreased interest in activities, and frequent thoughts about dying. She is started on nortriptyline to help improve her mood and functional status. Which of the following is a common side effect of nortriptyline?
Digoxin toxicity is increased by all except:
A patient on lithium therapy developed hypertension and was started on a thiazide diuretic. After a few days, he developed coarse tremors and other symptoms suggestive of lithium toxicity. What is the probable mechanism of interaction between thiazide diuretics and lithium?
Which antibiotic potentiates the effect of neuromuscular blockers?
Pharmacodynamic Interactions Indian Medical PG Practice Questions and MCQs
Question 1: Pharmacodynamics deals with:-
- A. Latency of onset
- B. Mechanism of action of a drug (Correct Answer)
- C. Transport of drug across the biological membranes
- D. Mode of excretion of a drug
Explanation: Detailed study of the **Mechanism of action of a drug** [1][2] - **Pharmacodynamics** describes what the **drug does to the body**, including its **molecular targets** and biochemical effects [3]. - This involves the study of the drug's mechanisms to produce its therapeutic or toxic effects [2]. *Latency of onset* - **Latency of onset** refers to the time it takes for a drug to start producing its effects, which is a pharmacokinetic rather than a pharmacodynamic parameter. - It deals with the drug's absorption and distribution rather than its interaction with the body once it reaches its site of action. *Transport of drug across the biological membranes* - The **transport of drugs across biological membranes** is a key aspect of **pharmacokinetics**, specifically absorption and distribution [1]. - This process determines how much drug reaches its target site, not how it interacts with the target. *Mode of excretion of a drug* - The **mode of excretion** of a drug (e.g., renal, hepatic) falls under **pharmacokinetics**, addressing how the body gets rid of the drug. - This process influences the drug's duration of action and elimination half-life, not its mechanism of action.
Question 2: Which of the following statements is true regarding competitive reversible antagonism?
- A. ED50 remains unchanged in competitive reversible antagonism.
- B. Efficacy and Vmax remain unchanged. (Correct Answer)
- C. Potency remains unchanged in the presence of a competitive antagonist.
- D. Affinity (Kd) remains unchanged in competitive reversible antagonism.
Explanation: ***Efficacy and Vmax remain unchanged.*** - In competitive reversible antagonism, the antagonist binds to the same receptor site as the agonist but can be overcome by increasing the agonist concentration [2]. This means the **maximum effect (efficacy or Vmax)** of the agonist can still be achieved, although a higher dose is needed [2]. - The antagonist does not alter the intrinsic ability of the agonist to produce a full response, only its **apparent affinity** for the receptor. - This is the hallmark of competitive reversible antagonism: **rightward shift of the dose-response curve with no change in maximum response** [2]. *Potency remains unchanged in the presence of a competitive antagonist.* - **Potency** is a measure of the amount of drug needed to produce a given effect (often defined by EC50 or ED50) [3]. - A competitive antagonist requires a **higher concentration of agonist** to achieve the same effect, thus **decreasing the apparent potency** of the agonist [4]. - The dose-response curve shifts to the right (parallel shift) [4]. *ED50 remains unchanged in competitive reversible antagonism.* - **ED50 (effective dose 50)** is the dose that produces 50% of the maximum effect. - Because competitive antagonists shift the dose-response curve to the right, a **higher ED50** is required to achieve 50% of the maximum effect in the presence of an antagonist [4]. *Affinity (Kd) remains unchanged in competitive reversible antagonism.* - The **dissociation constant (Kd)** represents the affinity of a drug for its receptor [1]. - In competitive reversible antagonism, the antagonist increases the **apparent Kd** of the agonist (reduces apparent affinity), requiring more agonist to achieve receptor occupancy. - The **intrinsic Kd** of the agonist doesn't change, but its apparent affinity is reduced due to competition with the antagonist.
Question 3: Which of the following is the most effective antagonist for morphine overdose?
- A. Buprenorphine
- B. Nalorphine
- C. Naloxone (Correct Answer)
- D. Pentazocine
Explanation: ***Naloxone*** - **Naloxone** is a pure opioid antagonist that rapidly reverses the effects of opioid overdose by competing for and displacing opioids from the **mu-opioid receptors** - Its rapid onset of action (1-2 minutes IV) and high affinity for opioid receptors make it the drug of choice for treating **morphine overdose**, particularly in emergency settings - Has no intrinsic agonist activity, making it safe and effective for acute reversal *Buprenorphine* - **Buprenorphine** is a partial opioid agonist, meaning it produces some opioid effects but to a lesser degree than full agonists like morphine - While it can displace full agonists from receptors, it is primarily used in **opioid dependence treatment** rather than acute overdose reversal - Has a ceiling effect for respiratory depression and is not the first-line agent for emergency overdose management *Nalorphine* - **Nalorphine** is an older mixed agonist-antagonist that was historically used for opioid overdose - It has largely been replaced by **naloxone** due to its own opioid-like effects (agonist activity at kappa receptors) and less favorable side effect profile - Can cause respiratory depression itself, making it unsuitable for emergency use *Pentazocine* - **Pentazocine** is an opioid agonist-antagonist (kappa agonist, mu antagonist), meaning it acts as an agonist at some opioid receptors and an antagonist at others - This mixed action means it can precipitate **withdrawal symptoms** in opioid-dependent individuals and is not suitable for reversing a full opioid overdose - Used primarily for analgesia, not overdose reversal
Question 4: Which of the following combinations does not show synergistic action?
- A. Streptomycin plus penicillin
- B. Rifampicin plus dapsone
- C. Penicillin plus tetracycline (Correct Answer)
- D. Penicillin plus sulfonamide
Explanation: ***Penicillin plus tetracycline*** - This combination is generally **antagonistic** or **indifferent**, not synergistic. Penicillin is a cell wall synthesis inhibitor that works best on actively growing bacteria, while tetracycline is a bacteriostatic protein synthesis inhibitor that can reduce bacterial growth, thereby diminishing penicillin's effect. - The combination is usually avoided as the **bacteriostatic action of tetracycline** can counteract the **bactericidal action of penicillin**, leading to reduced efficacy, especially in infections requiring rapid bacterial clearance. *Penicillin plus sulfonamide* - This combination can show synergism in some contexts, particularly as sulfonamides inhibit **folate synthesis**, while penicillin inhibits **cell wall synthesis**. - While not a classic synergistic pair for all infections, their mechanisms of action are distinct, and they can sometimes be used together, although specific synergistic effects are more limited compared to other pairs. *Streptomycin plus penicillin* - This is a classic example of **synergistic action**, particularly in conditions like **enterococcal endocarditis**. - Penicillin damages the bacterial cell wall, allowing **streptomycin** (an aminoglycoside) to more easily penetrate the cell and act on ribosomal targets, leading to enhanced bactericidal effect. *Rifampicin plus dapsone* - This combination is a cornerstone of **multi-drug therapy for leprosy**, demonstrating clear synergy against *Mycobacterium leprae*. - **Rifampicin** inhibits bacterial RNA synthesis, and **dapsone** inhibits folate synthesis, attacking different essential bacterial pathways which, when combined, are more effective and reduce the development of resistance.
Question 5: A patient on digoxin therapy presents with atrial fibrillation and controlled ventricular rate. Upon evaluation, the patient's serum digoxin levels are elevated compared to previous values. Which of the following concomitant medications is most likely to have contributed to the enhanced digoxin toxicity?
- A. Triamterene
- B. KCL
- C. Atenolol
- D. Clarithromycin (Correct Answer)
- E. Amiodarone
Explanation: ***Clarithromycin*** - **Clarithromycin** is a **macrolide antibiotic** known to inhibit the cytochrome P450 3A4 (CYP3A4) enzyme system and **P-glycoprotein**. - This inhibition leads to decreased metabolism and **efflux of digoxin**, resulting in **increased serum digoxin levels** and enhanced toxicity. - Among the options, clarithromycin is the **most common cause** of elevated digoxin levels through P-gp inhibition. *Triamterene* - **Triamterene** is a **potassium-sparing diuretic** that can increase serum potassium. - **Hyperkalemia** generally *reduces* the binding of digoxin to Na+/K+-ATPase, thereby potentially *reducing* its toxic effects. - Does not significantly affect digoxin serum levels. *KCL* - **Potassium chloride (KCl)** is used to correct **hypokalemia**. - **Hypokalemia** can *potentiate* digoxin toxicity because low potassium increases digoxin binding to the Na+/K+-ATPase pump. - However, KCl supplementation *corrects* hypokalemia and would actually *reduce* toxicity risk, not increase serum digoxin levels. *Atenolol* - **Atenolol** is a **beta-blocker** primarily used to control heart rate and blood pressure. - While it can slow the heart rate like digoxin (additive pharmacodynamic effect), it does not significantly alter the **pharmacokinetics** or serum levels of digoxin. *Amiodarone* - **Amiodarone** is an **antiarrhythmic** that can inhibit P-glycoprotein and increase digoxin levels. - However, in this scenario, **clarithromycin** is more commonly associated with acute elevations in digoxin levels in clinical practice. - Amiodarone interactions are well-known and typically require dose adjustments at initiation.
Question 6: Identify the correct match, regarding the drug and its adverse effect.
- A. Aliskiren - hypokalemia
- B. Hydralazine - heart failure
- C. Atenolol - hemolytic anemia
- D. Verapamil - constipation (Correct Answer)
Explanation: ***Verapamil - Constipation*** - **Verapamil**, a **non-dihydropyridine calcium channel blocker**, frequently causes constipation due to its effect on smooth muscle in the gastrointestinal tract, leading to **decreased intestinal motility**. - This adverse effect is common and often dose-dependent, making it a significant consideration in patient management. *Aliskiren - hypokalemia* - **Aliskiren**, a **direct renin inhibitor**, can cause **hyperkalemia** by reducing angiotensin II levels, which normally stimulate aldosterone secretion. - It does not typically cause hypokalemia; rather, potassium-sparing effects are often observed. *Hydralazine - heart failure* - **Hydralazine** is a **vasodilator** used to treat hypertension and **heart failure** with reduced ejection fraction by reducing afterload. - It does not cause heart failure; instead, it is often prescribed to improve cardiac function in patients with heart failure. *Atenolol - hemolytic anemia* - **Atenolol** is a **beta-blocker** primarily used for hypertension, angina, and arrhythmias. - **Hemolytic anemia** is a rare adverse effect associated with certain drugs, but it is not a known or common side effect of atenolol.
Question 7: A 78-year-old woman is brought to the clinic by her daughter due to concerns about her mother's mood. The patient's husband of 48 years passed away six months ago after a lengthy illness due to metastatic colon cancer. Since then, she reports having a poor appetite, decreased interest in activities, and frequent thoughts about dying. She is started on nortriptyline to help improve her mood and functional status. Which of the following is a common side effect of nortriptyline?
- A. weight loss
- B. impaired cardiac contractility
- C. heart block
- D. anticholinergic side effects (Correct Answer)
Explanation: ***Anticholinergic side effects*** - **Nortriptyline** is a **tricyclic antidepressant (TCA)** known for its significant **antimuscarinic** activity, leading to anticholinergic effects. - Common anticholinergic side effects include **dry mouth, blurred vision, constipation, urinary retention**, and **tachycardia**. *Impaired cardiac contractility* - While TCAs can have **cardiac effects** (e.g., QT prolongation, arrhythmias), **impaired cardiac contractility** is not a common or typical direct side effect at therapeutic doses. - Other drug classes, such as certain **beta-blockers** or **calcium channel blockers**, are more commonly associated with this effect. *Weight loss* - **Weight gain** is a more common side effect associated with many antidepressants, including some TCAs. - While some individuals may experience initial appetite changes, **sustained weight loss** is not a characteristic side effect of **nortriptyline**. *Heart block* - TCAs can cause **conduction abnormalities** like **prolonged QRS duration** and **QT interval prolongation**, especially in overdose or in patients with pre-existing cardiac conditions. - However, direct **heart block** (e.g., AV block) is a less common side effect, usually associated with higher doses or specific patient vulnerabilities.
Question 8: Digoxin toxicity is increased by all except:
- A. Hypercalcemia
- B. Hypomagnesemia
- C. Hyperkalemia (Correct Answer)
- D. Renal impairment
Explanation: ***Hyperkalemia*** - **Hyperkalemia** actually *reduces* the binding of digoxin to the Na+/K+ ATPase, thereby **decreasing** its pharmacological effect and the risk of toxicity. - While it can cause cardiac arrhythmias on its own, it does not increase the specific risk of digoxin toxicity. *Renal impairment* - **Digoxin** is primarily excreted by the **kidneys**, so **renal impairment** leads to reduced clearance and accumulation of the drug. - This increased drug concentration in the body significantly raises the risk of **digoxin toxicity**. *Hypercalcemia* - **Hypercalcemia** potentiates the effects of digoxin by increasing the intracellular calcium concentration, which can lead to enhanced contractility and increased risk of **arrhythmias**. - High calcium levels can exacerbate the cardiac side effects of digoxin toxicity, such as **AV blocks** and **ventricular arrhythmias**. *Hypomagnesemia* - **Hypomagnesemia** increases the binding of digoxin to the Na+/K+ ATPase, making the heart more sensitive to digoxin's effects. - Along with **hypokalemia**, **hypomagnesemia** is a common electrolyte imbalance that can precipitate or worsen digoxin toxicity, promoting **arrhythmias**.
Question 9: A patient on lithium therapy developed hypertension and was started on a thiazide diuretic. After a few days, he developed coarse tremors and other symptoms suggestive of lithium toxicity. What is the probable mechanism of interaction between thiazide diuretics and lithium?
- A. Thiazide increases the tubular reabsorption of lithium (Correct Answer)
- B. Thiazide inhibits the metabolism of lithium
- C. Thiazides act as an add-on drug to lithium
- D. None of the above
Explanation: ***Thiazide increases the tubular reabsorption of lithium*** - Thiazide diuretics cause a decrease in sodium reabsorption in the distal convoluted tubule, leading to increased sodium excretion in urine. - The kidneys, in an attempt to conserve sodium, increase reabsorption in the proximal tubule. Because **lithium** is reabsorbed similarly to sodium in the proximal tubule, this increased reabsorption also affects lithium, leading to a rise in its plasma concentration and toxicity. *Thiazide inhibits the metabolism of lithium* - Lithium is primarily excreted by the kidneys and is not significantly metabolized in the body. - Thiazide diuretics do not affect enzyme systems responsible for drug metabolism. *Thiazides act as an add on the drug to lithium* - This statement is vague and does not explain a mechanism of interaction leading to toxicity. - While both drugs might be prescribed concurrently for different conditions, "add on" does not describe a pharmacological interaction causing altered drug levels. *None of the above* - This option is incorrect because a clear and well-understood mechanism for the interaction between thiazide diuretics and lithium exists.
Question 10: Which antibiotic potentiates the effect of neuromuscular blockers?
- A. Erythromycin
- B. Aminoglycoside (Correct Answer)
- C. Nitrofurantoin
- D. Co-trimoxazole
Explanation: ***Aminoglycoside*** - **Aminoglycosides** inhibit presynaptic release of **acetylcholine** and suppress postsynaptic sensitivity to acetylcholine, thereby enhancing the effects of **neuromuscular blockers (NMBs)**. - This potentiation can lead to prolonged **neuromuscular blockade** and **respiratory depression**, especially in patients with impaired renal function or pre-existing neuromuscular disease. *Erythromycin* - **Erythromycin**, a **macrolide antibiotic**, is primarily known for inhibiting the **cytochrome P450 3A4 (CYP3A4)** enzyme, which can alter the metabolism of many drugs. - It does not directly impact **acetylcholine** release or receptor sensitivity to the extent that it significantly potentiates **neuromuscular blockers**. *Nitrofurantoin* - **Nitrofurantoin** is an **antibiotic** used predominantly for **urinary tract infections** and acts by damaging bacterial DNA and ribosomal proteins. - There is no known significant interaction or potentiation effect of **nitrofurantoin** on **neuromuscular blockers**. *Co-trimoxazole* - **Co-trimoxazole (trimethoprim-sulfamethoxazole)** is a combination **antibiotic** that interferes with bacterial **folic acid synthesis**. - It does not interfere with **neuromuscular transmission** or potentiate **neuromuscular blockers**, unlike aminoglycosides.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free